<!DOCTYPE html>
<html lang="en-US"><head>
		<meta charset="UTF-8">
		<title>FR940617-1-00068</title>
	</head>
	<body>
		<main>
			<p><!-- PJG STAG 4702 -->  <!-- PJG ITAG l=11 g=1 f=1 --> In this current tentative final monograph, the agency  <!-- PJG 0012 frnewline --> recognizes that the professional uses of povidone-iodine that are  <!-- PJG 0012 frnewline --> proposed as safe and effective are limited to a patient  <!-- PJG 0012 frnewline --> preoperative skin preparation, health-care personnel handwash,  <!-- PJG 0012 frnewline --> and surgical hand scrub. Further examination of the reference  <!-- PJG 0012 frnewline --> cited in the previous tentative final monograph (Ref. 3) reveals  <!-- PJG 0012 frnewline --> that the reported adverse effects were due to intravenous or  <!-- PJG 0012 frnewline --> parenteral use of povidone. Based on the more recent data and  <!-- PJG 0012 frnewline --> comments, the agency now believes that neither medium nor larger  <!-- PJG 0012 frnewline --> molecular weight povidone-iodine molecules present risks when  <!-- PJG 0012 frnewline --> limited to the topical uses included in this tentative final  <!-- PJG 0012 frnewline --> monograph. Larger molecules of povidone-iodine would not be  <!-- PJG 0012 frnewline --> absorbed if the drug is used for these professional uses in  <!-- PJG 0012 frnewline --> accordance with the monograph. Thus, there is no need for the  <!-- PJG 0012 frnewline --> professional labeling to limit the molecular weight of  <!-- PJG 0012 frnewline --> povidone-iodine products or to require special warnings related  <!-- PJG 0012 frnewline --> to the molecular weight of povidone-iodine. Accordingly, such  <!-- PJG 0012 frnewline --> labeling is not being included in this tentative final monograph.  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->   <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=74 g=1 f=1 --> References <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=21 g=1 f=1 --> (1) Sindelar, W.F., and Mason, G.R.,  <!-- PJG 0012 frnewline --> ``Irrigation of Subcutaneous Tissue With  <!-- PJG 0012 frnewline --> Povidone-Iodine Solution for Prevention of  <!-- PJG 0012 frnewline --> Surgical Wound Infections,''  <!-- PJG /ITAG -->  <!-- PJG ITAG l=21 g=1 f=3 --> Surgery,  <!-- PJG 0012 frnewline --> Gynecology and Obstetrics, <!-- PJG /ITAG -->  <!-- PJG ITAG l=21 g=1 f=1 -->  148:227&hyph;231, 1979.  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> (2) Unpublished review of published and  <!-- PJG 0012 frnewline --> unpublished studies regarding lymph node  <!-- PJG 0012 frnewline --> changes and effect on the reticuloendothelial  <!-- PJG 0012 frnewline --> system resulting from use of PVP-iodine on  <!-- PJG 0012 frnewline --> intact skin, mucous membranes, and open  <!-- PJG 0012 frnewline --> wounds, Comment No. C111 (vol. III A), Docket  <!-- PJG 0012 frnewline --> No. 75N&hyph;0183, Dockets Management Branch.  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> (3) Unpublished review of published  <!-- PJG 0012 frnewline --> studies regarding intravenous or parenteral  <!-- PJG 0012 frnewline --> use of polyvinylpyrrolidone (PVP), Comment  <!-- PJG 0012 frnewline --> No. C40, Docket No. 75N&hyph;0183, Dockets  <!-- PJG 0012 frnewline --> Management Branch.  <!-- PJG /ITAG -->  <!-- PJG QTAG 04 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG ITAG l=11 g=1 f=1 --> 19. Several comments contended that there are numerous  <!-- PJG 0012 frnewline --> professional uses for povidone-iodine, particularly uses that  <!-- PJG 0012 frnewline --> involve medical devices, that were not discussed by the Panel or  <!-- PJG 0012 frnewline --> by the agency in the tentative final monograph. These  <!-- PJG 0012 frnewline --> professional uses include catheter care, ostomy hygiene, patient  <!-- PJG 0012 frnewline --> skin scrubbing prior to preoperative prepping, surgical site  <!-- PJG 0012 frnewline --> cleansing after stitching, mouth and throat swabbing, treatment  <!-- PJG 0012 frnewline --> of the skin before covering a fracture with a cast, antiseptic  <!-- PJG 0012 frnewline --> treatment of various scalp problems, and intravenous site  <!-- PJG 0012 frnewline --> preparation. One comment added that a pharmacist or other health  <!-- PJG 0012 frnewline --> professional may recommend the use of povidone-iodine as a  <!-- PJG 0012 frnewline --> douche, perianal wash, or whirlpool concentrate. The comments  <!-- PJG 0012 frnewline --> requested that special labeling be added to the monograph to cover all of these uses, but did not submit data regarding these  <!-- PJG 0012 frnewline --> uses.  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> One comment also provided professional labeling for  <!-- PJG 0012 frnewline --> povidone-iodine used for urinary or intravenous catheter care  <!-- PJG 0012 frnewline --> procedures. The suggested labeling included the following terms:  <!-- PJG 0012 frnewline --> ``antiseptic,'' ``germicide,'' ``microbicidal,'' and ``for hospital and  <!-- PJG 0012 frnewline --> professional use.''  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> Several of the professional uses mentioned by the comments  <!-- PJG 0012 frnewline --> are not covered by this rulemaking, but they will be addressed  <!-- PJG 0012 frnewline --> under other OTC drug rulemakings. For example, the use of  <!-- PJG 0012 frnewline --> povidone-iodine for mouth and throat swabbing is included in the  <!-- PJG 0012 frnewline --> advance notice of proposed rulemaking for OTC oral health care  <!-- PJG 0012 frnewline --> drug products, published in the  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=4 --> Federal Register <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  of May 25, 1982  <!-- PJG 0012 frnewline --> (47 FR 22760). The use of povidone-iodine for the treatment of  <!-- PJG 0012 frnewline --> scalp problems is addressed in the final rule for OTC dandruff,  <!-- PJG 0012 frnewline --> seborrheic dermatitis, and psoriasis drug products, published in  <!-- PJG 0012 frnewline --> the  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=4 --> Federal Register <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  of December 4, 1991 (56 FR 63554). The use  <!-- PJG 0012 frnewline --> of povidone-iodine as a douche is addressed in the advance notice  <!-- PJG 0012 frnewline --> of proposed rulemaking for OTC vaginal drug products, published  <!-- PJG 0012 frnewline --> in the  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=4 --> Federal Register <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  of October 13, 1983 (48 FR 46694).  <!-- PJG 0012 frnewline --> The Advisory Review Panel on OTC Hemorrhoidal Drug Products  <!-- PJG 0012 frnewline --> stated that the inclusion of antiseptics in OTC anorectal drug  <!-- PJG 0012 frnewline --> products ``is useful in concept,'' but ``that proof of any  <!-- PJG 0012 frnewline --> significant clinical benefit of claimed antiseptic ingredients  <!-- PJG 0012 frnewline --> must be demonstrated in clinical trials'' (45 FR 35576 at 35659).  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> That Panel believed that, because of the large numbers of micro-organisms present in feces, there is little likelihood that  <!-- PJG 0012 frnewline --> effective antisepsis could be obtained in the anorectal area with  <!-- PJG 0012 frnewline --> antiseptics any more than with soap and water. Because no data  <!-- PJG 0012 frnewline --> were submitted on povidone-iodine as a perianal wash, the agency  <!-- PJG 0012 frnewline --> did not address this ingredient in the discussion of antiseptics  <!-- PJG 0012 frnewline --> in the tentative final monograph for OTC anorectal drug products  <!-- PJG 0012 frnewline --> when the agency evaluated the Panel's conclusions. Similarly,  <!-- PJG 0012 frnewline --> the ingredient was not included in the final rule for OTC  <!-- PJG 0012 frnewline --> anorectal drug products, published in the  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=4 --> Federal Register <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  of  <!-- PJG 0012 frnewline --> August 3, 1990 (55 FR 31766). Parties interested in this use of  <!-- PJG 0012 frnewline --> povidone-iodine can submit data and information as part of a  <!-- PJG 0012 frnewline --> citizen petition to amend the final rule for OTC anorectal drug  <!-- PJG 0012 frnewline --> products. (See 21 CFR 10.30.)  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG /STAG --></p>
		</main>
</body></html>
            